Plexxikon begins arthritis drug study
The first Phase I clinical trial is a single-ascending dose study in 32 healthy volunteers, while the second trial is a multiple-ascending dose study in 32 RA patients
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
According to the company, the Berinert marketing approval is given on the basis of positive results from Phase II/III prospective, double-blind placebo-controlled International Multi-center Prospective Angioedema C1-Inhibitor Trial
Bioserve’s services include Phase I & Bioavailability/Bioequivalence studies, PK in Patient Populations, Bioanalytical Services, Statistical & IVIVC Analysis, Pharmacoscintigraphic Imaging, Clinical Trial Management and Regulatory Affairs. QPS president
Earlier, Takeda collaborated with its wholly-owned subsidiaries Takeda San Francisco, Millennium Pharmaceuticals, Takeda Bio Development Center and Chemistry, Manufacturing and Controls (CMC) Center to commercialize new drug candidate